Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.39 |
| ▸ | KRAS | P01116 | 4/20 | 0.35 |
| ▸ | ATR | Q13535 | 4/20 | 0.35 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292288 | 1.00 | USP30 (0.39) | USP30KRASATRHTR3AKMT2A | |
| SCHEMBL30150795 | 1.00 | USP30 (0.39) | USP30KRASATRHTR3AKMT2A | |
| SCHEMBL21296336 | 0.87 | CNR2 (0.38) | HTR3AKMT2ASMYD3 | |
| SCHEMBL21292249 | 0.84 | DYRK1A (0.46) | HTR3ASMYD3 | |
| SCHEMBL21292250 | 0.84 | DYRK1A (0.46) | HTR3ASMYD3 | |
| SCHEMBL21292340 | 0.81 | HTR3A (0.37) | HTR3AKMT2ASMYD3 | |
| SCHEMBL21292352 | 0.76 | TRPV1 (0.37) | HTR3AKMT2A | |
| SCHEMBL21292357 | 0.76 | PDE7A (0.41) | HTR3A | |
| SCHEMBL21292360 | 0.76 | PDE7A (0.41) | HTR3A | |
| SCHEMBL21292351 | 0.76 | TRPV1 (0.37) | HTR3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3755696-B1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112020501-A | 5-heteroaryl substituted indazol-3-yl carboxamides, their preparation and use | 萨穆梅德有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20190263821-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | USP30 4750/4885KRAS 2375/4885ATR 4117/4885 |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | USP30 4750/4885KRAS 2375/4885ATR 4117/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | USP30 4750/4885KRAS 2375/4885ATR 4117/4885 |
| US-20190263821-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | USP30 4750/4885KRAS 2375/4885ATR 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.